Yes I agree on the long term CSL will do well with $1B R&D budget. But on the short term with this uncertainty on their revenue, I doubt investors will be paying high PE multiple. CSL will have to demonstrate some visible potential products which are almost ready for the market or Vifor & Vaccine business come up with compensating increase in revenue. I think that is there issue at the moment.
Yes I agree on the long term CSL will do well with $1B R&D...
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$284.23 |
Change
2.890(1.03%) |
Mkt cap ! $135.9B | |||
| Open | High | Low | Value | Volume |
| $283.00 | $284.64 | $282.50 | $17.52M | 60.80K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 236 | $284.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $284.23 | 19 | 3 |
View Market Depth
| Last trade - 10.16am 04/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$283.94 |
Change
2.890 ( 1.05 %) |
||||
| Open | High | Low | Volume | ||
| $283.00 | $284.55 | $283.00 | 1656 | ||
| Last updated 10.35am 04/06/2024 ? | |||||
| CSL (ASX) Chart |